echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > [Approved] Qilu won 500 million oral hypoglycemic drugs!

    [Approved] Qilu won 500 million oral hypoglycemic drugs!

    • Last Update: 2021-04-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On March 17, the official website of the State Food and Drug Administration showed that Qilu Pharmaceutical's Saxagliptin tablets were approved for submission in the generic 4 categories.


    On March 17, 2021, the drug approval document pending information is released -1

    Data show that saxagliptin is a potent and selective dipeptidyl peptidase-4 (DPP-4) inhibitor, which can prolong endogenous glucagon-like peptide-1 (GLP) by inhibiting DPP-4.


    Sales of terminal saxagliptin tablets in Chinese public medical institutions in recent years

    Source: Terminal competition landscape of China's public medical institutions

    Saxagliptin tablets were developed by Bristol-Myers Squibb.


    Up to now, there are 5 manufacturers of saxagliptin tablets, and Qilu Pharmaceutical is the fourth domestic manufacturer.


    Source: official website of the State Food and Drug Administration, Mi Nei.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.